Cargando…
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250/ https://www.ncbi.nlm.nih.gov/pubmed/27571185 http://dx.doi.org/10.1210/jc.2016-2300 |
_version_ | 1782465267846086656 |
---|---|
author | de Filette, Jeroen Jansen, Yanina Schreuer, Max Everaert, Hendrik Velkeniers, Brigitte Neyns, Bart Bravenboer, Bert |
author_facet | de Filette, Jeroen Jansen, Yanina Schreuer, Max Everaert, Hendrik Velkeniers, Brigitte Neyns, Bart Bravenboer, Bert |
author_sort | de Filette, Jeroen |
collection | PubMed |
description | CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction. DESIGN AND SETTING: Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access program at a referral oncology center. (18)Fluorodeoxyglucose uptake on positron emission tomography/computed tomography ((18)FDG-PET/CT) was reviewed in cases compatible with inflammatory thyroiditis. PATIENTS: Ninety-nine patients with advanced melanoma (age, 26.3–93.6 years; 63.6% females) who received at least one administration of pembrolizumab. MAIN OUTCOME MEASURES: Patient characteristics, thyroid function (TSH, free T(4)), thyroid autoantibodies, and (18)FDG-PET/CT. RESULTS: Eighteen adverse events of thyroid dysfunction were observed in 17 patients. Thyrotoxicosis occurred in 12 patients, of which nine evolved to hypothyroidism. Isolated hypothyroidism was present in six patients. Levothyroxine therapy was required in 10 of 15 hypothyroid patients. Thyroid autoantibodies were elevated during thyroid dysfunction in four of 10 cases. Diffuse increased (18)FDG uptake by the thyroid gland was observed in all seven thyrotoxic patients who progressed to hypothyroidism. CONCLUSIONS: Thyroid dysfunction is common in melanoma patients treated with pembrolizumab. Hypothyroidism and thyrotoxicosis related to inflammatory thyroiditis are the most frequent presentations. Serial measurements of thyroid function tests are indicated during anti-PD-1 monoclonal antibody therapy. Thyrotoxicosis compatible with inflammatory thyroiditis was associated with diffuse increased (18)FDG uptake by the thyroid gland. The prospective role of thyroid autoantibodies should be further investigated, together with the histopathological correlates. |
format | Online Article Text |
id | pubmed-5095250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-50952502016-11-28 Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab de Filette, Jeroen Jansen, Yanina Schreuer, Max Everaert, Hendrik Velkeniers, Brigitte Neyns, Bart Bravenboer, Bert J Clin Endocrinol Metab Original Articles CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction. DESIGN AND SETTING: Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access program at a referral oncology center. (18)Fluorodeoxyglucose uptake on positron emission tomography/computed tomography ((18)FDG-PET/CT) was reviewed in cases compatible with inflammatory thyroiditis. PATIENTS: Ninety-nine patients with advanced melanoma (age, 26.3–93.6 years; 63.6% females) who received at least one administration of pembrolizumab. MAIN OUTCOME MEASURES: Patient characteristics, thyroid function (TSH, free T(4)), thyroid autoantibodies, and (18)FDG-PET/CT. RESULTS: Eighteen adverse events of thyroid dysfunction were observed in 17 patients. Thyrotoxicosis occurred in 12 patients, of which nine evolved to hypothyroidism. Isolated hypothyroidism was present in six patients. Levothyroxine therapy was required in 10 of 15 hypothyroid patients. Thyroid autoantibodies were elevated during thyroid dysfunction in four of 10 cases. Diffuse increased (18)FDG uptake by the thyroid gland was observed in all seven thyrotoxic patients who progressed to hypothyroidism. CONCLUSIONS: Thyroid dysfunction is common in melanoma patients treated with pembrolizumab. Hypothyroidism and thyrotoxicosis related to inflammatory thyroiditis are the most frequent presentations. Serial measurements of thyroid function tests are indicated during anti-PD-1 monoclonal antibody therapy. Thyrotoxicosis compatible with inflammatory thyroiditis was associated with diffuse increased (18)FDG uptake by the thyroid gland. The prospective role of thyroid autoantibodies should be further investigated, together with the histopathological correlates. Endocrine Society 2016-11 2016-08-29 /pmc/articles/PMC5095250/ /pubmed/27571185 http://dx.doi.org/10.1210/jc.2016-2300 Text en http://creativecommons.org/licenses/by-nc/4.0/ This article is published under the terms of the Creative Commons Attribution-Non Commercial License (CC-BY-NC; http://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Original Articles de Filette, Jeroen Jansen, Yanina Schreuer, Max Everaert, Hendrik Velkeniers, Brigitte Neyns, Bart Bravenboer, Bert Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title_full | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title_fullStr | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title_full_unstemmed | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title_short | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
title_sort | incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250/ https://www.ncbi.nlm.nih.gov/pubmed/27571185 http://dx.doi.org/10.1210/jc.2016-2300 |
work_keys_str_mv | AT defilettejeroen incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT jansenyanina incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT schreuermax incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT everaerthendrik incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT velkeniersbrigitte incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT neynsbart incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab AT bravenboerbert incidenceofthyroidrelatedadverseeventsinmelanomapatientstreatedwithpembrolizumab |